An inherited drug-transport defect travels through a line of ancestors as a recessive trait: a dog must inherit one altered copy of the gene from each parent to be affected, while a dog with a single copy looks normal and can still pass the alteration on. Because carriers show no sign of the defect, a paper pedigree alone cannot tell you which ancestors carried it. The only way to know where a dog sits in that chain is to combine the pedigree with a documented test result, and then use both when planning a breeding.
How does an inherited drug-transport defect travel through a line of ancestors?
Most inherited drug-transport defects in dogs involve a gene that codes for P-glycoprotein, a protein that pumps certain drugs out of the brain and other tissues. When the gene is altered on both copies, the pump does not work properly, and drugs such as ivermectin reach the central nervous system at levels that cause toxicity. The pattern is autosomal recessive, which means the trait is not tied to sex and does not appear unless both copies are altered.
That single fact explains how the defect moves through a line. An affected dog has two altered copies, one from the sire and one from the dam. Each of those parents had at least one altered copy, so each was either a carrier or affected. Going back another generation, each grandparent of an affected dog had at least one altered copy as well. The trait can therefore be present in a family for many generations without a single affected puppy, because carriers are healthy and are usually bred as normal dogs.
A paper pedigree shows the shape of that chain but not its content. It tells you which dogs are related, how closely, and through which ancestors. It does not tell you which of those dogs carried an altered copy. Two littermates can look identical on paper and differ completely in what they pass on. This is why a pedigree is a map of risk, not a diagnosis.
For anyone working through a breed archive, the exercise is the same whether the dog is a herding breed or a terrier: you follow the ancestors, note where a test result exists, and mark where it does not. A resource such as reading a Bull Terrier pedigree shows how generations, registration records and breeding affixes are laid out, which is the same structure you need when you trace a recessive trait through any line. The pedigree gives you the names and the relationships; the test results give you the genotype.
What does a test result add to a paper pedigree?
A DNA test for the relevant gene adds the one thing a pedigree cannot supply: the actual genotype of an individual dog. For a recessive defect, a test normally sorts a dog into one of three states. Clear means both copies are normal. Carrier means one copy is altered and one is normal. Affected means both copies are altered.
That result changes how you read every ancestor behind the dog. If a tested dog is clear, it cannot have passed an altered copy to its offspring, so the chain stops there on that side. If a tested dog is a carrier, the alteration is confirmed in that line, and each parent of that dog must have had at least one altered copy. If a tested dog is affected, both parents were at least carriers, and the trait is confirmed on both sides of the family.
A test result is also permanent information. It applies to that dog for life and does not change with age, illness or environment. A pedigree, by contrast, is a record of descent that grows as new litters are registered. The two work together: the pedigree tells you where to look, and the test tells you what you found.
One limitation matters. A clear result on one dog says nothing about an untested sibling, cousin or grandparent. Recessive traits hide in exactly those untested relatives. A single clear test is a data point, not a clearance of the whole line. Breeders who understand this treat each result as one tile in a larger picture and keep testing across generations rather than relying on one ancestor's paperwork.
Why can a breed without a common MDR1 association still carry an affected dog?
Breed associations are statistical patterns, not biological rules. When a defect is described as common in certain breeds, that statement reflects how often it has been found in those populations. It does not mean the alteration is absent elsewhere, and it does not mean every dog in an associated breed carries it.
An alteration that is recessive can persist at low frequency in any population where carriers are bred. If a carrier is used at stud, the alteration spreads into the next generation quietly. Over time it can appear in a breed that no one associates with the defect, simply because an ancestor from an associated line was introduced, or because the alteration was already present at low frequency and no one tested for it.
This is why a diagnosis in an unexpected breed is not a contradiction. It is a signal that testing should widen. A dog that reacts severely to a drug at a dose most dogs tolerate deserves a genetic explanation, regardless of breed. The clinical picture and the test result carry more weight than the breed label.
For owners, the practical consequence is straightforward. Do not assume a breed is safe because it is not on a list. If a dog has had a severe reaction to a drug that is normally well tolerated, discuss genetic testing with a veterinarian. If a dog is being considered for breeding and any ancestor came from a line where the defect is known, test before the mating rather than after the litter.
How is the answer used in a breeding decision?
The genotype of each prospective parent drives the decision. The goal in a recessive condition is not to remove every carrier from breeding, which would shrink the gene pool and can push breeders toward other problems. The goal is to avoid producing affected puppies while keeping useful dogs in the population.
A clear dog bred to a clear dog produces clear puppies, assuming the test covers the relevant alteration. A clear dog bred to a carrier produces a litter in which each puppy has a chance of being clear or a carrier, but none will be affected. A carrier bred to a carrier is the combination that can produce affected puppies, and it is the pairing to avoid when a clear alternative exists. An affected dog bred to any dog will pass one altered copy to every puppy, so all puppies will be at least carriers.
In practice, breeders use three tools together. The first is the pedigree, which shows how closely the two dogs are related and whether a known carrier appears in both backgrounds. The second is the test result for each dog, which converts a probability into a fact. The third is the wider health picture of the line, because a single gene is not the only thing a breeding decision has to weigh.
When a test result is unavailable, the pedigree still has value. It can show that a proposed pairing would concentrate an ancestor that produced an affected dog, which raises the risk. In that situation, testing the dogs before breeding is the reasonable step, and testing the puppies afterward is a fallback if the mating has already happened. Either way, the information belongs in the record so the next person reading the pedigree has it.
What owners should take from this
A recessive drug-transport defect is invisible in a healthy carrier and can travel through many generations of a pedigree without announcement. The pedigree shows the path; a DNA test shows what is actually on it. Breed associations describe where a defect has been found often, not where it is allowed to exist, so an affected dog in an unexpected breed is a reason to test rather than a reason to doubt the diagnosis. Used together, the paper record and the test result let a breeder choose pairings that avoid affected puppies while keeping the line intact, and let an owner understand why a drug that suits most dogs may not suit theirs.
The figures and inheritance rules summarized here follow the standard description of the MDR1 defect and its protein product, which is maintained in the P-glycoprotein reference entry. That entry explains how a recessive drug-transport defect can pass silently through several generations before two carriers produce an affected puppy. It also supports the testing logic used above: a DNA result identifies carriers that a paper pedigree alone cannot reveal, which matters when a breed has no common MDR1 association. Owners can use the same reasoning when they review a pedigree or plan a mating.